Cardioxyl Pharmaceuticals is an early-stage therapeutics company that is commercializing a novel discovery from the laboratories of David Kass and Nazareno Paolocci at Johns Hopkins University, who have identified unique nitroxyl donors to treat cardiovascular disease. The company was founded in 2005 and is located in Durham, NC. Acquired by: Bristol-Myers Squibb